Shares of Celgene, a biotech blue-chip stock that generates most of its revenue from the development of oncology, inflammation, and immunology drugs, dipped 11% in November, based on data from S&P ...

Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of ...

In a sudden management revamp, Celgene President and COO Scott Smith will leave his post at the biotech company, effective immediately. Celgene has recently suffered from a series of major setbacks ...

Crohn’s disease continues to be an area with significant unmet demand and limited treatment options. Based on its high efficacy and tolerability, GED-0301 can become preferred regimen for patients ...

Celgene’s shares have dropped nearly 30 percent since October, due to slow sales of its psoriasis drug Otezla, an upcoming patent cliff for its multiple myeloma drug Revlimid, and the failure of an ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market ...

Biopharmaceutical firm Celgene Corp. (CELG) focuses on various cancers including multiple myeloma and myelodysplastic syndromes, chronic lymphocyte leukemia and non-Hodgkin’s lymphoma, and ovarian, ...

NEW YORK, Nov 18 (Reuters) - Biotechnology company Celgene Corp will buy Pharmion Corp for about $2.9 billion in stock and cash, the companies said on Sunday, in a deal that boosts Celgene's push into ...

The Food and Drug Administration on Tuesday approved Celgene Corp.’s cancer drug for use with a companion diagnostic test developed by Abbott Laboratories. Idhifa is used to treat adults with relapsed ...